CLINICAL EFFICACY AND SAFETY OF THE DRUG NEUROOXIDOL-ZOMMER (250 MG/5 ML) IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR ACCIDENTS

Olimov Elbek Alisherovich; Mangasaryan Arsen Arsenovich; Tursunov Makhmud Mukhammadovich; Tulaboyeva Gavkhar Mirakbarovna

Authors

Olimov Elbek Alisherovich Fergana Branch of the Republican Scientific Center for Emergency Medical Care Central Asian Medical University Cardiac Surgeon
Mangasaryan Arsen Arsenovich Central Asian Medical University Cardiologist, Uromed Clinic
Tursunov Makhmud Mukhammadovich Central Asian Medical University General Practitioner, Uromed Clinic
Tulaboyeva Gavkhar Mirakbarovna Center for the Development of Professional Qualifications of Medical Workers Department of Cardiology and Gerontology with the Course of Interventional Cardiology and Arrhythmology

Keywords:

Chronic cerebral ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyridine succinate, Neurooxidol-Zommer (250 mg/5 ml), cognitive impairment.

Abstract

Objective of the study. To study the efficacy and safety of sequential therapy with Neurooxidol-Zommer (250 mg/5 ml), administered intravenously by drip for 14 days, in elderly patients with chronic cerebral ischemia (CCI) against the background of arterial hypertension and atherosclerosis. Material and methods. The open prospective observational study included 60 patients with an established diagnosis of CCI, confirmed by the results of neuroimaging. All patients were examined to assess the neuropsychological status (MoCA test), severity of asthenia (MFI-20 scale), emotional state (Hamilton Anxiety and Depression Scale), motor functions (Tinetti Formalized Clinical Scale for Assessing the Motor Activity of the Elderly). The effectiveness of the therapy was assessed using the quality-of-life questionnaire (SF-36). The study results showed high efficacy and safety of sequential therapy with Neurooxidol-Zommer (250 mg/5 ml) in relieving asthenic and emotional disorders, improving cognitive functions, and increasing the quality of life of patients. The maximum effect occurred after the completion of the full course of therapy. High patient compliance with the therapy and a low incidence of adverse events were shown. Sequential use of intravenous administration of Neurooxidol-Zommer (250 mg/5 ml) is an effective and safe method of treating patients with CCI.